On-demand PrEP before and after sexual activity could reduce the incidence of HIV-1 in men who have sex with men.
PrEP
Latest News
Advertisement
CME Content
Advertisement
The public fear of human immunodeficiency virus has diminished since the 1980s crisis, and now many health care professionals are seeing less urgency surrounding HIV prevention and treatment.
While health care providers generally favor pre-exposure prophylaxis (PrEP) for patients at high risk of acquiring human immunodeficiency virus (HIV), many hesitate to actually prescribe it.
HIV antiviral therapy can prevent infection from establishing in at-risk individuals.
The pharmacist's role as a disease educator is moving to the forefront.
There have been significant increases in the cost of antiretroviral therapies (ART) for individual therapies and in the cost of therapy initiation over the past several years.
The latest advances in HIV treatment and care include new drug therapies, a new at-home test, and updates guidelines for antiretroviral therapy for pregnant women.
Patients taking Truvada may still significantly reduce their risk of HIV infection even when they are not 100% adherent to their drug regimens, a new study revealed.
The FDA approved Truvada for preexposure prophylaxis, making it the first agent ever to be approved for HIV prevention in uninfected adults.
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
2
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5
